Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Tengion, Inc.

Market Cap 1L 94.59T 87.1T 81.78T 2L 1.04Cr 2L 10.29L 4L 50.81L 4L 4L 1.76Cr P/E Ratio 2012
-0.14x
P/E Ratio 2013 -0.05x
Enterprise Value 55.52L 47.85L 44.06L 41.37L 77.67L 52Cr 78.49L 5.21Cr 2.03Cr 26Cr 2.08Cr 2.04Cr 89Cr EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0
5 years 0
Extreme 0
0.02
10 years 0
Extreme 0
0.04
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 40
+0.54%-0.27%-38.23%-35.43% 55Cr
+0.40%+2.32%+260.34% - 53Cr
-0.42%+0.75%-33.96%+24.06% 14Cr
-5.14%-12.98%+48.24%+85.53% 13Cr
Average -0.92%-1.53%+59.10%+24.72% 26.88Cr
Weighted average by Cap. -0.15%-0.40%+87.68%-6.48%

Financials

2012 2013
Net sales - -
Net income -1.69Cr -1.46Cr -1.34Cr -1.26Cr -2.37Cr -160.06Cr -2.39Cr -16Cr -6.18Cr -78Cr -6.35Cr -6.22Cr -271.63Cr -1.89Cr -1.63Cr -1.5Cr -1.41Cr -2.65Cr -178.95Cr -2.68Cr -18Cr -6.91Cr -88Cr -7.1Cr -6.95Cr -303.69Cr
Net Debt 37.33L 32.17L 29.62L 27.81L 52.22L 35Cr 52.77L 3.5Cr 1.36Cr 17Cr 1.4Cr 1.37Cr 60Cr 54.42L 46.9L 43.19L 40.55L 76.13L 51Cr 76.93L 5.1Cr 1.99Cr 25Cr 2.04Cr 2Cr 87Cr
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
26
  1. Stock Market
  2. Stocks
  3. TNGN.Q Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!